GAMMA Investing LLC Has $5.76 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

GAMMA Investing LLC increased its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 5,916.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,175 shares of the biotechnology company's stock after purchasing an additional 127,028 shares during the period. GAMMA Investing LLC owned approximately 0.26% of Vericel worth $5,764,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wellington Management Group LLP increased its holdings in shares of Vericel by 119.3% in the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after acquiring an additional 701,064 shares in the last quarter. California State Teachers Retirement System raised its holdings in Vericel by 4.6% during the 4th quarter. California State Teachers Retirement System now owns 45,857 shares of the biotechnology company's stock worth $2,518,000 after buying an additional 2,014 shares during the period. Mackenzie Financial Corp acquired a new stake in Vericel during the 4th quarter worth approximately $215,000. GF Fund Management CO. LTD. bought a new position in Vericel in the fourth quarter valued at approximately $57,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Vericel by 17.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 112,837 shares of the biotechnology company's stock valued at $6,196,000 after buying an additional 16,466 shares during the period.

Vericel Trading Up 4.3%

Shares of Vericel stock traded up $1.88 during trading hours on Tuesday, reaching $45.70. 352,512 shares of the company's stock were exchanged, compared to its average volume of 417,779. The stock has a market cap of $2.30 billion, a P/E ratio of 761.79 and a beta of 1.33. The company has a 50 day moving average of $41.25 and a two-hundred day moving average of $50.02. Vericel Co. has a fifty-two week low of $37.39 and a fifty-two week high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last released its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.14). The company had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business's revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. As a group, analysts expect that Vericel Co. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VCEL has been the topic of a number of research analyst reports. Truist Financial dropped their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a report on Friday, April 11th. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vericel in a research note on Friday, February 28th. Stephens restated an "overweight" rating and issued a $67.00 price target on shares of Vericel in a report on Thursday, May 22nd. Finally, Wall Street Zen downgraded Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Vericel presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.14.

Insider Activity

In related news, CEO Dominick Colangelo sold 26,592 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76. Following the completion of the sale, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This trade represents a 9.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.20% of the stock is currently owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.